Application of an expert system in the management of HIV-infected patients

被引:15
作者
Pazzani, MJ
See, D
Schroeder, E
Tille, J
机构
[1] UNIV CALIF IRVINE, DEPT MED, ORANGE, CA 92868 USA
[2] UNIV CALIF IRVINE, DEPT INFORMAT & COMP SCI, ORANGE, CA 92868 USA
关键词
AIDS; expert program; PCR; cloning; sequencing; antiretrovirals;
D O I
10.1097/00042560-199708150-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A rule-based expert system, Customized Treatment Strategies for HIV (CTSHIV), which encodes information from the literature on known drug-resistant mutations was developed. Additional rules include ranking and weighting based on antiviral activities, redundant mechanisms of action, overlapping toxicities, relative levels of drug-resistance, and proportion of drug-resistant clones in the HIV quasispecies. Plasma was obtained from HIV-infected patients and the RNA was extracted. Segments of the HIV pol gene encoding the entire protease, reverse transcriptase, and integrase proteins were amplified by reverse transcriptase-polymerase chain reaction (using a total of three primer pairs) and cloned. Sequencing was performed on five clones from each of two patients. When the patient's RNA sequencing data were entered into the expert program, and the information was downloaded directly into the CTSHIV program, the five most effective two, three, and four drug regimens coupled with an explanation for their choice were displayed for each patient. Thus, the CT-SHIV system couples efficient genetic sequencing with an expert program that recommends regimens based on information in the current medical literature. It may serve as a useful tool in the design of clinical trials and in the management of HIV-infected patients.
引用
收藏
页码:356 / 362
页数:7
相关论文
共 48 条
[1]  
[Anonymous], 1990, INTRO EXPERT SYSTEMS
[2]  
Boucher C, 1996, AIDS, V10, pS15
[3]   ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS [J].
BOUCHER, CAB ;
OSULLIVAN, E ;
MULDER, JW ;
RAMAUTARSING, C ;
KELLAM, P ;
DARBY, G ;
LANGE, JMA ;
GOUDSMIT, J ;
LARDER, BA .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :105-110
[4]   Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication [J].
Caliendo, AM ;
Savara, A ;
An, D ;
DeVore, K ;
Kaplan, JC ;
DAquila, RT .
JOURNAL OF VIROLOGY, 1996, 70 (04) :2146-2153
[6]   Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor [J].
Condra, JH ;
Holder, DJ ;
Schleif, WA ;
Blahy, OM ;
Danovich, RM ;
Gabryelski, LJ ;
Graham, DJ ;
Laird, D ;
Quintero, JC ;
Rhodes, A ;
Robbins, HL ;
Roth, E ;
Shivaprakash, M ;
Yang, T ;
Chodakewitz, JA ;
Deutsch, PJ ;
Leavitt, RY ;
Massari, FE ;
Mellors, JW ;
Squires, KE ;
Steigbigel, RT ;
Teppler, H ;
Emini, EA .
JOURNAL OF VIROLOGY, 1996, 70 (12) :8270-8276
[7]   ANTIVIRAL THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTIONS [J].
DECLERCQ, E .
CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (02) :200-239
[8]   A MUTATION IN REVERSE-TRANSCRIPTASE OF BIS(HETEROARYL)PIPERAZINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 THAT CONFERS INCREASED SENSITIVITY TO OTHER NONNUCLEOSIDE INHIBITORS [J].
DUEWEKE, TJ ;
PUSHKARSKAYA, T ;
POPPE, SM ;
SWANEY, SM ;
ZHAO, JQ ;
CHEN, ISY ;
STEVENSON, M ;
TARPLEY, WG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (10) :4713-4717
[9]   GENERATION AND CHARACTERIZATION OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) MUTANT RESISTANT TO AN HIV-1 PROTEASE INHIBITOR [J].
ELFARRASH, MA ;
KURODA, MJ ;
KITAZAKI, T ;
MASUDA, T ;
KATO, K ;
HATANAKA, M ;
HARADA, S .
JOURNAL OF VIROLOGY, 1994, 68 (01) :233-239
[10]   PCR AMPLIFICATION OF HIV-1 PROTEINASE SEQUENCES DIRECTLY FROM LAB ISOLATES ALLOWS DETERMINATION OF 5 CONSERVED DOMAINS [J].
FONTENOT, G ;
JOHNSTON, K ;
COHEN, JC ;
GALLAHER, WR ;
ROBINSON, J ;
LUFTIG, RB .
VIROLOGY, 1992, 190 (01) :1-10